SABCS 2022 Conference Coverage


 

SABCS 2022 Primary Results of the Randomized Phase 3 DESTINY-Breast02 Study: T-DXd vs. Physician’s Choice in HER2+ Unresectable and/or mBC Previously Treated With Trastuzumab Emtansine

154 views
January 5, 2023
Comments 0
Login to view comments. Click here to Login